Treprostinil (Orenitram, Tyvaso, Yutrepia) — 2026 Medicare Part D coverage
treprostinil — sold as Orenitram, Tyvaso, Yutrepia: 21 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover treprostinil?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| Yutrepia 106 MCG Inhalation Powder brand · RxCUI 2714676 | 117 (36%) | 5 | 115 | 0 | 53 |
| Yutrepia 26.5 MCG Inhalation Powder brand · RxCUI 2714664 | 117 (36%) | 5 | 115 | 0 | 53 |
| Yutrepia 53 MCG Inhalation Powder brand · RxCUI 2714668 | 117 (36%) | 5 | 115 | 0 | 53 |
| Yutrepia 79.5 MCG Inhalation Powder brand · RxCUI 2714672 | 117 (36%) | 5 | 115 | 0 | 53 |
| Orenitram 0.125 MG 12HR Extended Release Oral Tablet brand · RxCUI 1488667 | 111 (34%) | 4 | 111 | 0 | 5 |
| Orenitram 0.25 MG 12HR Extended Release Oral Tablet brand · RxCUI 1488671 | 111 (34%) | 5 | 111 | 0 | 4 |
| Orenitram 1 MG 12HR Extended Release Oral Tablet brand · RxCUI 1488675 | 111 (34%) | 5 | 111 | 0 | 4 |
| Orenitram 2.5 MG 12HR Extended Release Oral Tablet brand · RxCUI 1488679 | 111 (34%) | 5 | 111 | 0 | 4 |
| Orenitram 5 MG 12HR Extended Release Oral Tablet brand · RxCUI 1858833 | 111 (34%) | 5 | 111 | 0 | 4 |
| Orenitram Month 1 Titration Kit brand · RxCUI 2630667 | 99 (30%) | 5 | 99 | 0 | 34 |
| Orenitram Month 2 Titration Kit brand · RxCUI 2630669 | 99 (30%) | 5 | 99 | 0 | 34 |
| Orenitram Month 3 Titration Kit brand · RxCUI 2630671 | 99 (30%) | 5 | 99 | 0 | 34 |
| TYVASO DPI 16 MCG Inhalation Powder brand · RxCUI 2602754 | 19 (6%) | 5 | 17 | 0 | 4 |
| TYVASO DPI 32 MCG Inhalation Powder brand · RxCUI 2602758 | 19 (6%) | 5 | 17 | 0 | 4 |
| TYVASO DPI 48 MCG Inhalation Powder brand · RxCUI 2602762 | 19 (6%) | 5 | 17 | 0 | 4 |
| TYVASO DPI 64 MCG Inhalation Powder brand · RxCUI 2602766 | 19 (6%) | 5 | 17 | 0 | 4 |
| Tyvaso DPI 16-32-48 MCG Titration Pack brand · RxCUI 2602770 | 19 (6%) | 5 | 17 | 0 | 4 |
| TYVASO DPI 80 MCG Inhalation Powder brand · RxCUI 2697739 | 17 (5%) | 5 | 17 | 0 | 4 |
| Tyvaso DPI 32-64 MCG Maintenance Pack brand · RxCUI 2641907 | 17 (5%) | 5 | 17 | 0 | 4 |
| Tyvaso DPI 48-64 MCG Maintenance Pack brand · RxCUI 2641912 | 17 (5%) | 5 | 17 | 0 | 4 |
| Tyvaso DPI 48-80 MCG Maintenance Pack brand · RxCUI 2727471 | 17 (5%) | 5 | 17 | 0 | 4 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.